

Antipsychotic Treatment Selector

Charts revised February 2023. Full information available at www.hiv-druginteractions.org

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

	ATV/c	ATV/r	DRV/c	DRV/r	LPV/r	DOR	EFV	ETV	NVP	RPV oral	FTR	LEN	MVC	BIC/F/TAF	CAB oral	CAB/RPV	DTG	EVG/c/F/TAF	EVG/c/F/TDF	RAL	FTC/TAF	FTC/TDF
Atypical Antipsychotics																						
Amisulpride	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Aripiprazole	↑♥	↑♥	↑	↑	↑♥	↔	↓	↓	↓	↔♥	↔♥	↑	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Asenapine	↑♥	↓♥	↑	↓♥	↓♥	↔	↓	↓	↓	↔♥	↔♥	↔	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Clozapine	↑♥	↑♥	↑	↑	↑♥	↔	↓	↓	↓	↔♥	↔♥	↑	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Olanzapine	↔	↓	↔	↓	↓	↔	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Paliperidone	↑♥	↑♥	↑	↑	↑♥	↔	↓	↓	↓	↔♥	↔♥	↔	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Quetiapine	↑a♥	↑a♥	↑a	↑a	↑a♥	↔	↓	↓	↓	↔	↔	↑	↔	↔	↔	↔	↔	↑a	↑a	↔	↔	↔
Risperidone	↑♥	↑♥	↑	↑	↑♥	↔	↓	↓	↓	↔	↔	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Zotepine	↑♥	↑♥	↑	↑	↑♥	↔	↓	↓	↓	↔♥	↔♥	↑	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Phenothiazines																						
Chlorpromazine	↑♥	↑♥	↑	↑	↑♥	↔	↔	↔	↔	↔♥	↔♥	↔	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Fluphenazine	↑♥	↑♥	↑	↑	↑♥	↔	↔	↔	↔	↔♥	↔♥	↔	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Levomepromazine	↑♥	↑♥	↑	↑	↑♥	↔	↔	↔	↔	↔♥	↔♥	↔	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Perazine	↑	↑	↑	↑	↑	↔	↓	↓	↓	↔	↔	↑	↔	↔	↔	↔	↔	↑	↑	↔	↔	↔
Periciazine	↑	↑	↑	↑	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑	↔	↔	↔
Perphenazine	↑♥	↑♥	↑	↑	↑♥	↔	↔	↔	↔	↔♥	↔♥	↔	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Pimozide	↑♥	↑♥	↑	↑	↑♥	↔	↑b	↓	↓	↔♥	↔♥	↑	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Prochlorperazine	↑♥	↑♥	↑	↑	↑♥	↔	↔	↔	↔	↔♥	↔♥	↔	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Thioridazine	↑♥	↑♥	↑	↑	↑♥	↓	↓	↓	↓	↓♥	↔♥	↑↓	↓	↓c	↔	↓	↔	↑	↑	↔	↔	↔
Others																						
Haloperidol	↑♥	↑♥	↑	↑	↑♥	↔	↓	↓	↓	↔♥	↔♥	↑	↑	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
lloperidone	↑♥	↑♥	↑	↑	↑♥	↔	↓	↓	↓	↔♥	↔♥	↑	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Pipotiazine	↑♥	↑♥	↑	↑	↑♥	↔	↔	↔	↔	↔♥	↔♥	↔	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Sulpiride	↔♥	↔♥	↔	↔	↔♥	↔	↔	↔	↔	↔♥	↔♥	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔	↔
Tiapride	↔♥	↔♥	↔	↔	↔♥	↔	↔	↔	↔	↔♥	↔♥	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔	↔
Ziprasidone	↑♥	↑♥	↑	↑	↑♥	↔	↓	↓	↓	↔♥	↔♥	↔	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Zuclophenthixol	↑♥	↑♥	↑	↑	↑♥	↔	↓	↓	↓	↔♥	↔♥	↑	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔

Interactions with CAB/RPV long acting injections

Pharmacokinetic interactions shown are mostly with RPV. QT interactions shown are with RPV.

Interactions with Lenacapavir

Residual LEN may affect exposure of sensitive CYP3A4 substrates initiated within 9 months after stopping subcutaneous LEN.

Interactions with Ibalizumab

None

Interactions with Abacavir (ABC), Lamivudine (3TC), Tenofovir-DF (TDF) or Zidovudine (ZDV)

ABC: No clinically relevant interactions expected.

3TC: No clinically relevant interactions expected.

TDF: No clinically relevant interactions expected.

ZDV: Potential additive haematological toxicity with chlorpromazine, clozapine, fluphenazine, periciazine, perphenazine, pipotiazine, quetiapine, thioridazine, zuclophenthixol.

Colour Legend

- No clinically significant interaction expected.
- These drugs should not be coadministered.
- Potential interaction which may require a dose adjustment or close monitoring.
- Potential interaction predicted to be of weak intensity. No *a priori* dosage adjustment is recommended.

Text Legend

- ↑ Potential increased exposure of the antipsychotic
- ↓ Potential decreased exposure of the antipsychotic
- ↔ No significant effect
- ↔♥ One or both drugs may cause QT and/or PR prolongation. ECG monitoring is advised if coadministered with atazanavir or lopinavir. Rilpivirine and fostemsavir were shown to prolong the QT interval at supratherapeutic doses. Caution is advised with rilpivirine. ECG monitoring is advised with fostemsavir and drugs with a known QT prolongation risk.
- ↑↑ Potential increased exposure of HIV drug
- ↓↓ Potential decreased exposure of HIV drug

Notes

- a Coadministration contraindicated in the European SPC however US Prescribing Information recommends quetiapine should be reduced to one sixth of the original dose if coadministered with a potent CYP3A4 inhibitor. The charts reflect the more cautious option.
- b Coadministration contraindicated in the European SPC but not in the US Prescribing Information for Sustiva. The charts reflect the more cautious option.
- c No effect on FTC or TAF is expected, but bicitgravir concentrations may decrease.